Tabriz University of Medical Sciences About    Newsletter    Contact Us    Create Account    Log in  
Advanced Pharmaceutical Bulletin
ISSN: 2228-5881      eISSN: 2251-7308  
Services
Export citation
EndNote
Reference Manager
BibTeX
Medlars
Refworks
Mendeley

Cite by
Google Scholar



Article History
Submitted: 18 Jul 2016
Revised: 22 Sep 2016
Accepted: 26 Oct 2016
First published online: 22 Dec 2016

Article Access Statistics
Abstract Page Views: 206
PDF Downloads: 230
Full Text Views: 0

Adv Pharm Bull. 2016;6(4):563-571 doi: 10.15171/apb.2016.070

Development of a Novel Human Single Chain Antibody Against EGFRVIII Antigen by Phage Display Technology



Research Article

Leila Rahbarnia 1,2, Safar Farajnia 1 * , Hossein Babaei 1, Jafar Majidi 3, Bahman Akbari 4, Shiva Ahdi khosroshahi 1

1 Drug Applied Research Center, Tabriz University of Medical Sciences, Tabriz, Iran.
2 Student Research Committee, Tabriz University of Medical Sciences, Tabriz, Iran.
3 Immunology Research Center, Tabriz University of Medical Sciences, Tabriz, Iran.
4 Biotechnology Research Center, Tabriz University of Medical Sciences, Tabriz, Iran.



Abstract
Purpose: EGFRvIII as the most common mutant variant of the epidermal growth factor receptor is resulting from deletion of exons 2–7 in the coding sequence and junction of exons 1 and 8 through a novel glycine residue. EGFRvIII is highly expressed in glioblastoma, carcinoma of the breast, ovary, and lung but not in normal cells. The aim of the present study was identification of a novel single chain antibody against EGFRvIII as a promising target for cancer therapy. Methods: In this study, a synthetic peptide corresponding to EGFRvIII protein was used for screening a naive human scFv phage library. A novel five-round selection strategy was used for enrichment of rare specific clones. Results: After five rounds of screening, six positive scFv clones against EGFRvIII were selected using monoclonal phage ELISA, among them, only three clones had expected size in PCR reaction. The specific interaction of two of the scFv clones with EGFRvIII was confirmed by indirect ELISA. One phage clone with higher affinity in scFv ELISA was purified for further analysis. The purity of the produced scFv antibody was confirmed using SDS-PAGE and Western blotting analyses. Conclusion: In the present study, a human anti- EGFRvIII scFv with high affinity was first identified from a scFv phage library. This study can be the groundwork for developing more effective diagnostic and therapeutic agents against EGFRvIII expressing cancers.





Comments
First name  
Last name  
Email address  
Comments  
Security code



This Article
PDF

Google Scholar
Articles by Rahbarnia L
Articles by Farajnia S
Articles by Babaei H
Articles by Majidi J
Articles by Akbari B
Articles by Ahdi khosroshahi S

PubMed
Articles by Rahbarnia L
Articles by Farajnia S
Articles by Babaei H
Articles by Majidi J
Articles by Akbari B
Articles by Ahdi khosroshahi S



Share this article!

Press Manuscript Online. Powered by MAADRAYAN